BioCentury | May 23, 2018
Translation in Brief

Toward Tailored Chemo

...the map showed cells lacking ARID1A or collagen type IV α 3 binding protein (COL4A3BP; GPBP...
...that poor clinical outcomes and resistance to platinum-based therapies were linked to ARID1A (p=0.01) or COL4A3BP...
...associated with PARP inhibitor resistance.” Cell Reports (2018) Jennie Walters, Staff Writer UCSF AT rich interactive domain 1A (ARID1A) Collagen type IV alpha 3 binding protein (COL4A3BP) (GPBP)...
BioCentury | May 15, 2018
Distillery Techniques

Biomarkers; other

...ARID1A) and resistance to platinum-based chemotherapy in collagen type IV α 3 binding protein (COL4A3BP; GPBP)-negative...
...in HGSOC patients receiving platinum-based chemotherapy confirmed the model’s predictions that loss of ARID1A and COL4A3BP...
...Francisco, San Francisco, Calif. email: sourav.bandyopadhyay@ucsf.edu Jennie Walters University of California San Francisco AT rich interactive domain 1A (ARID1A) Collagen type IV alpha 3 binding protein (COL4A3BP) (GPBP) Ovarian...
BioCentury | Dec 5, 2011
Product Development

Change-up for BATTER-UP

...matrix-remodeling associated 7 (MXRA7) , chromosome X open reading frame 52 (CXorf52) , collagen type IV alpha 3 binding protein (COL4A3BP...
BioCentury | May 16, 2005
Company News

NephroGenex, Biomedical Research Foundation, Karolinska Institute deal

...NephroGenex acquired exclusive commercialization rights to the foundation's inhibitors of goodpasture antigen binding protein (GPBP) kinase...
Items per page:
1 - 4 of 4